Surrozen, Inc. Common (SRZN) is a publicly traded Healthcare sector company. As of May 21, 2026, SRZN trades at $27.16 with a market cap of $318.59M and a P/E ratio of -0.64. SRZN moved +4.50% today. Year to date, SRZN is +41.62%; over the trailing twelve months it is +219.37%. Its 52-week range spans $5.90 to $35.00. Analyst consensus is strong buy with an average price target of $42.50. Rallies surfaces SRZN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Surrozen Holds $106.9M Cash After $5M Boehringer Milestone in Q1: Surrozen ended Q1 2026 with $106.9 million in cash, up from $89.2 million at Q4 2025, and booked a $5.0 million Boehringer Ingelheim milestone payment. The company incurred $9.3 million in R&D costs and is on track to file an IND for SZN-8141 in H2 2026.
| Metric | Value |
|---|---|
| Price | $27.16 |
| Market Cap | $318.59M |
| P/E Ratio | -0.64 |
| EPS | $-41.34 |
| Dividend Yield | 0.00% |
| 52-Week High | $35.00 |
| 52-Week Low | $5.90 |
| Volume | 2 |
| Avg Volume | 0 |
| Revenue (TTM) | $7.49M |
| Net Income | $-342.56M |
| Gross Margin | 0.00% |
5 analysts cover SRZN: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $42.50.